Clinical trialPhase 2Unknown
The First Line Treatment of Fruquintinib Combined With Albumin Paclitaxel and Gemcitabine in Pancreatic Cancer Patients
An Open Single-center Phase II Clinical Study of Fruquintinib Combined With Chemotherapy in Patients With Liver Metastases From Pancreatic Cancer
- Outcome
- Outcome unknown
- Phase
- Phase 2
- Status
- Unknown
- Study type
- Interventional
- Start
- 3 September 2021
- Expected end
- 31 May 2024
- Enrollment
- 30 participants
- Sites
- 1
- Primary outcomes
- ORR
- Sponsor
- Other
- Results posted
- No
- Last update
- 14 January 2022
These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess. Only its metadata is loaded so far, so most questions will be declined.
Try
Papers 17
- BackgroundEffect of Fruquintinib vs Placebo on Overall Survival in Patients With Previously Treated Metastatic Colorectal Cancer:… DOI 10.1001/jama.2018.7855↗
- BackgroundGemcitabine/nab-paclitaxel as second-line therapy following FOLFIRINOX in metastatic/advanced pancreatic cancer-retrosp… DOI 10.21037/jgo.2017.01.23↗
- BackgroundEvaluation of gemcitabine efficacy after the FOLFIRINOX regimen in patients with advanced pancreatic adenocarcinoma. DOI 10.1097/md.0000000000006544↗
- BackgroundPANCREOX: A Randomized Phase III Study of Fluorouracil/Leucovorin With or Without Oxaliplatin for Second-Line Advanced … DOI 10.1200/jco.2016.68.5776↗
- BackgroundA Phase I study of safety and pharmacokinetics of fruquintinib, a novel selective inhibitor of vascular endothelial gro… DOI 10.1007/s00280-016-3069-8↗
- BackgroundCA19-9 decrease at 8 weeks as a predictor of overall survival in a randomized phase III trial (MPACT) of weekly nab-pac… DOI 10.1093/annonc/mdw006↗
- BackgroundRole of gemcitabine as second-line therapy after progression on FOLFIRINOX in advanced pancreatic cancer: a retrospecti… DOI 10.3978/j.issn.2078-6891.2015.041↗
- BackgroundNab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective … DOI 10.1038/bjc.2015.328↗
- BackgroundProjecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the Un… DOI 10.1158/0008-5472.can-14-0155↗
- BackgroundIncreased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. DOI 10.1056/nejmoa1304369↗
- BackgroundStromal disrupting effects of nab-paclitaxel in pancreatic cancer. DOI 10.1038/bjc.2013.415↗
- BackgroundRandomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced a… DOI 10.1200/jco.2012.43.3680↗
- BackgroundMeta-analysis of phase III randomized trials of molecular targeted therapies for advanced pancreatic cancer. DOI 10.1111/j.1477-2574.2012.00441.x↗
- BackgroundGemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial. DOI 10.1200/jco.2011.36.5742↗
- BackgroundFOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. DOI 10.1056/nejmoa1011923↗
- BackgroundA meta-analysis of gemcitabine containing chemotherapy for locally advanced and metastatic pancreatic adenocarcinoma. DOI 10.1186/1756-8722-4-11↗
- BackgroundNew response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). DOI 10.1016/j.ejca.2008.10.026↗